Capecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer: final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trial
Crossref DOI link: https://doi.org/10.1007/s10549-016-3727-x
Published Online: 2016-02-29
Published Print: 2016-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Welt, A.
Marschner, N.
Lerchenmueller, C.
Decker, T.
Steffens, C.-C.
Koehler, A.
Depenbusch, R.
Busies, S.
Hegewisch-Becker, S.
License valid from 2016-02-01